The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight /Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis
Table 2
Characteristics of the studies included in the meta-analysis.
Study ID
Intervention
Control
Type (dose)
N
Age
BWB (kg)
WCB (cm)
BMIB (kg/m2)
Type (dose)
N
Age
BWB (kg)
WCB (cm)
BMIB (kg/m2)
(BWC)
(WCC)
(BMIC)
(BWC)
(WCC)
(BMIC)
1
EXE (10 μg BID)
14
28.2 ± 4.9
110.5 ± 26.8 (−3.2 ± 0.4)
40.3 ± 8.9 (−1.0 ± 1.1)
MET (1000 mg BID)
7
27.7 ± 5.8
113.4 ± 31.3 (−1.6 ± 0.8)
43.3 ± 8.9 (−1.0 ± 1.1)
2
EXE (10 μg BID) + MET (1000 mg BID)
14
32.1 ± 3.1
112.0 ± 35.8 (−6.0 ± 1.9)
40.9 ± 8.9 (−1.7 ± 1.1)
MET (1000 mg BID)
7
27.7 ± 5.8
113.4 ± 31.3 (−1.6 ± 0.8)
43.3 ± 8.9 (−1.0 ± 1.1)
3
LIRA (1.2 mg QD)
11
31.5 ± 6.4
108.9 ± 15.1 (−3.8 ± 3.7)
124.9 ± 9.9 (−3.2 ± 2.9)
39.3 ± 4.2 (−1.3 ± 1.3)
MET (1000 mg BID)
7
31.3 ± 9.4
103.2 ± 6.3 (−1.2 ± 1.4)
122.3 ± 7.0 (−1.6 ± 2.9)
36.6 ± 3.5 (−0.5 ± 0.5)
4
LIRA (1.2 mg QD) + MET (1000 mg BID)
11
31.1 ± 5.1
105.5 ± 20.6 (−6.5 ± 2.8)
121.9 ± 17.7 (−5.5 ± 3.8)
37.6 ± 5.1 (−2.4 ± 1.0)
MET (1000 mg BID)
7
31.3 ± 9.4
103.2 ± 6.3 (−1.2 ± 1.4)
122.3 ± 7.0 (−1.6 ± 2.9)
36.6 ± 3.5 (−0.5 ± 0.5)
5
LIRA (1.2 mg QD)
14
29.5 ± 7.7
113.7 ± 18.7 (−3.0 ± 3.4)
128.5 ± 13.9 (−4.4 ± 5.0)
41.6 ± 5.3 (−1.1 ± 1.1)
MET (1000 mg BID)
14
25.3 ± 5.2
103.6 ± 19.7 (−2.3 ± 2.6)
121.6 ± 17.1 (−2.6 ± 3.0)
37.4 ± 6.4 (−0.9 ± 0.9)
6
LIRA (1.2 mg QD)
14
30.7 ± 7.9
102.8 ± 16.3 (−3.1 ± 3.5)
115.7 ± 12.5 (−3.1 ± 2.8)
36.7 ± 5.6 (−1.1 ± 1.3)
MET (1000 mg BID)
13
30.7 ± 7.9
108.3 ± 17.0 (−0.2 ± 1.8)
120.5 ± 14.5 (0.8 ± 1.9)
39.4 ± 6.9 (−0.1 ± 0.7)
7
EXE (10 μg BID)
80
27.9 ± 2.7
73.0 ± 9.8 (−4.3 ± 1.3)
93.0 ± 10.1 (−9.0 ± 3.8)
29.2 ± 3.1 (−3.1 ± 1.4)
MET (1000 mg BID)
78
27.7 ± 3.8
70.4 ± 4.6 (−2.3 ± 0.6)
89.4 ± 6.6 (−5.0 ± 4.7)
28.3 ± 1.9 (−1.0 ± 0.2)
8
LIRA (1.2 mg QD) + MET (1000 mg BID)
14
30.1 ± 3.6
106.6 ± 11.7 (−7.5 ± 3.9)
114.5 ± 9.9 (−11.7 ± 9.0)
37.8 ± 3.0 (−2.7 ± 1.3)
MET (1000 mg BID)
14
31.1 ± 4.7
99.6 ± 17.8 (−7.0 ± 6.0)
108.8 ± 14.5 (−11.3 ± 9.2)
35.5 ± 4.9 (−2.5 ± 2.0)
BID: twice daily; QD: once daily; BWB: body weight baseline (kg); BWC: body weight changes (kg); WCB: waist circumference baseline (cm); WCC: waist circumference changes (cm); BMIB: body mass index baseline (kg/m2); BMIC: body mass index changes (kg/m2); EXE: exenatide; LIRA: liraglutide; MET: metformin.